United Kingdom of Great Britain and Northern IrelandTuberculosis profile
Population  2015 65 million
Estimates of TB burden*, 2015 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.3 (0.29–0.3) 0.46 (0.46–0.46)
Mortality (HIV+TB only) 0.038 (<0.01–0.21) 0.06 (0–0.32)
Incidence  (includes HIV+TB) 6.6 (6–7.2) 10 (9.2–11)
Incidence (HIV+TB only) 0.31 (0.25–0.38) 0.48 (0.38–0.59)
Incidence (MDR/RR-TB)** 0.11 (0.072–0.15) 0.17 (0.11–0.23)
Estimated TB incidence by age and sex (thousands)*, 2015
  0-14 years > 14 years Total
Females 0.25 (0.15–0.35) 2.5 (1.9–3) 2.7 (2.1–3.4)
Males 0.3 (0.21–0.38) 3.6 (2.8–4.3) 3.9 (3.1–4.7)
Total 0.55 (0.43–0.66) 6 (5.7–6.4) 6.6 (6–7.2)
TB case notifications, 2015  
Total cases notified 6 240
Total new and relapse 5 854
          - % tested with rapid diagnostics at time of diagnosis 5%
          - % with known HIV status 81%
          - % pulmonary 53%
          - % bacteriologically confirmed among pulmonary 76%
Universal health coverage and social protection  
TB treatment coverage (notified/estimated incidence), 2015 89% (81–98)
TB patients facing catastrophic total costs  
TB case fatality ratio (estimated mortality/estimated incidence), 2015 0.05 (0.04–0.07)
TB/HIV care in new and relapse TB patients, 2015 Number (%)
Patients with known HIV-status who are HIV-positive    
          - on antiretroviral therapy    
Drug-resistant TB care, 2015 New cases Previously treated
cases
Total
number***
Estimated MDR/RR-TB cases among notified
pulmonary TB cases
  58
(39–77)
Estimated % of TB cases with MDR/RR-TB 1.4% (0.98–2) 3.4% (1.1–7.9)  
% notified tested for rifampicin resistance 58% 51% 3 759
MDR/RR-TB cases tested for resistance to second-line drugs   53
Laboratory-confirmed cases MDR/RR-TB: 57, XDR-TB: 10
Patients started on treatment **** MDR/RR-TB: 62, XDR-TB: 10
Treatment success rate and cohort size Success Cohort
New and relapse cases registered in 2014 81% 6 512
Previously treated cases, excluding relapse, registered in 2014 72% 450
HIV-positive TB cases, all types, registered in 2014    
MDR/RR-TB cases started on second-line treatment in 2013 65% 77
XDR-TB cases started on second-line treatment in 2013 33% 3
TB preventive treatment, 2015  
% of HIV-positive people (newly enrolled in care) on preventive treatment  
% of children (aged < 5) household contacts of bacteriologically-confirmed
TB cases on preventive treatment
 
TB financing, 2016  
National TB budget (US$ millions)  
* Ranges represent uncertainty intervals
** MDR is TB resistant to rifampicin and isoniazid; RR is TB resistant to rifampicin
*** Includes cases with unknown previous TB treatment history
**** Includes patients diagnosed before 2015 and patients who were not laboratory-confirmed
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population per year)
Incidence graph
   Incidence
   Notified (new and relapse)
   Incidence (HIV+TB only)

Notified cases by age group and sex, 2015
age_sex_graph
____
FemalesMales

Treatment success rate (%)
tx success graph
   
New and relapse
   Retreatment, excluding relapse
   HIV-positive   MDR/RR-TB   XDR-TB

 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-12-11 Data: www.who.int/tb/data